Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av NT-175 hos voksne personer med uoperable, avanserte og/eller metastatiske solide svulster som er positive for HLA-A*02:01 og TP53 R175H-mutasjonen

28. september 2026 oppdatert av: AstraZeneca

En åpen, fase 1, multisenterstudie for å evaluere sikkerheten og den foreløpige antitumoraktiviteten til NT-175 i humant leukocyttantigen-A*02:01-positive voksne individer med uoperable, avanserte og/eller metastatiske solide svulster som er Positivt for TP53 R175H-mutasjonen

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

Studieoversikt

Detaljert beskrivelse

This is a Phase 1, open-label, multicentre platform study to evaluate the safety and preliminary antitumour activity of NT-175 in HLA-A*02:01 participants with advanced malignancies that are positive for the TP53 R175H mutation.

Dose Escalation will investigate escalating doses of NT-175 in adult subjects with eligible histologies and will evaluate the safety and MTD and/or RDE/RP2D.

Cohort expansion will further evaluate the safety and preliminary anti-tumour activity at or below the MTD in disease specific histologies and determine the RP2D.

Dose Expansion will further evaluate the preliminary anti-tumour activity and safety of NT-175 at the RP2D in disease specific settings.

Studietype

Intervensjonell

Registrering (Antatt)

45

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Arizona
      • Gilbert, Arizona, Forente stater, 85234
        • Rekruttering
        • Research Site
    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • Research Site
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • Research Site
      • Newport Beach, California, Forente stater, 92663
        • Rekruttering
        • Research Site
      • Santa Monica, California, Forente stater, 90404
        • Rekruttering
        • Research Site
    • Florida
      • Jacksonville, Florida, Forente stater, 32224
        • Rekruttering
        • Research Site
      • Miami, Florida, Forente stater, 33136
        • Tilbaketrukket
        • Research Site
      • Tampa, Florida, Forente stater, 33612
        • Tilbaketrukket
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Research Site
      • Boston, Massachusetts, Forente stater, 02115
        • Rekruttering
        • Research Site
    • New Jersey
      • New Brunswick, New Jersey, Forente stater, 08901
        • Rekruttering
        • Research Site
    • New York
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28204
        • Tilbaketrukket
        • Research Site
      • Winston-Salem, North Carolina, Forente stater, 27103
        • Tilbaketrukket
        • Research Site
    • Oregon
      • Portland, Oregon, Forente stater, 97213
        • Rekruttering
        • Research Site
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • Rekruttering
        • Research Site
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Research Site
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Research Site
      • Round Rock, Texas, Forente stater, 78665
        • Rekruttering
        • Research Site
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria (Module 1)

  • Subjects must be at least 18 years of age

  • Subject must be diagnosed with one of the histologies below:

    • NSCLC
    • Colorectal adenocarcinoma
    • HNSCC
    • Pancreatic adenocarcinoma
    • Breast cancer
    • Ovarian cancer
    • Any other solid tumor
  • Tumors must harbor a TP53 R175H variant mutation and subject must be HLA-A*02:01 positive (at least 1 allele)

  • Subject has advanced solid cancer, defined as unresectable, advanced, and/or metastatic disease (Stage III or IV) after at least 1 line of approved systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options.

  • Subject has at least 1 measurable lesion

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

  • Adequate hematological, renal, hepatic, pulmonary, and cardiac function

Key Exclusion Criteria (Module 1)

  • Any another primary malignancy within the 3 years prior to enrollment
  • Known, active primary central nervous system (CNS) malignancy
  • History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.
  • History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.
  • Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment.
  • Any form of primary immunodeficiency.
  • Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.

Key Inclusion Criteria (Module 2 - hematological malignancies)

  • At least 18 years of age
  • Diagnosis of AML or MDS that allows for efficacy assessments
  • Confirmation of TP53 R175H variant mutation in cancer cells
  • Subject must be HLA-A*02:01 positive (at least 1 allele)
  • ECOG performance status of 0 to 1

Key Exclusion Criteria (Module 2 - hematological malignancy)

  • Acute promyelocytic leukaemia or isolated extramedullary disease
  • Another primary malignancy within 2 years (with exceptions)
  • HSCT within 100 days or immunosuppression for GvHD within 4 weeks
  • History of CNS or other extramedullary leukaemic involvement unless a lumbar puncture is negative for leukemic cells
  • Prior stroke, ischemic attack, significant cardiac disease, heart failure
  • Prior adoptive modified cell therapy
  • Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: NT-175 for advanced malignancies

TCR T cell therapy product

  • Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide
  • Single infusion Autologous, engineered T Cells targeting TP53 R175H
  • Post-infusion recombinant interleukin-2 (rIL-2)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
Tidsramme: 28 days after infusion

Incidence of dose-limiting toxicities (DLTs) after the infusion of NT-175

28 days after infusion
Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
Tidsramme: Up to 24 months post-infusion

Incidence of Treatment Emergent Adverse Events (TEAE) Serious Adverse Events (SAE)

Up to 24 months post-infusion
Module 1, Part 2: Preliminary anti-tumour activity of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
Tidsramme: Up to 24 months after infusion

Per RECIST v1.1 determined by Investigator assessment:

  • Objective Response Rate (ORR)
  • Best Overall Response (BOR)
  • Duration of Response (DOR)
  • Clinical Benefit Rate (CBR)
  • Time to Response (TTR)
  • Progression-free survival (PFS)
  • Overall Survival (OS)
Up to 24 months after infusion
Module 2: Safety of NT-175 in participants with haematological malignancies
Tidsramme: Up to 28 days after infusion

- Incidence of dose-limiting toxicities (DLTs) after the infusion of NT-175

Up to 28 days after infusion
Module 2: Safety of NT-175 in participants with haematological malignancies
Tidsramme: Up to 24 months after infusion
  • Incidence of Treatment Emergent Adverse Events (TEAE)
  • Serious Adverse Events (SAE)
Up to 24 months after infusion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Module 1, Part 1: Preliminary anti-tumor activity of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
Tidsramme: Up to 24 months after infusion

Per RECIST v1.1 determined by Investigator assessment:

  • Objective Response Rate (ORR)
  • Best Overall Response (BOR)
  • Duration of Response (DOR)
  • Clinical Benefit Rate (CBR)
  • Time to Response (TTR)
  • Progression-free survival (PFS)
  • Overall Survival (OS)
Up to 24 months after infusion
Module 2: Evaluate preliminary anti-tumour activity in participants with AML or MDS
Tidsramme: Up to 24 months after infusion

Per ELN 2022 criteria for AML and per IWG 2023 criteria for MDS by Investigator assessment:

  • Objective Response Rate (ORR)
  • Time to Response (TTR)
  • Duration of Response (DOR)
  • Event-free survival (EFS)

By Investigator assessment:

  • Transfusion Independence (TI)
  • Overall Survival (OS)
  • Complete Response (CR) + Complete response with partial haematological recover (CRh)
  • Complete Response with limited count recovery (CRL) (CRuni + CRbi) in MDS
  • MDS time to Progression to AML
  • Proportion of participants with subsequent Haematopoietic Stem Cell Transplantation (HSCT)
Up to 24 months after infusion

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: AstraZeneca, AstraZeneca

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. juli 2023

Primær fullføring (Antatt)

31. juli 2029

Studiet fullført (Antatt)

31. juli 2029

Datoer for studieregistrering

Først innsendt

17. mai 2023

Først innsendt som oppfylte QC-kriteriene

17. mai 2023

Først lagt ut (Faktiske)

26. mai 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tilgangskriterier for IPD-deling

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere